Table of Contents

A perspective on the treatment of acute lymphoblastic leukemia in adults.
Acute lymphocytic leukemia: clinical features and making the diagnosis.
The biology of adult acute lymphoblastic leukemia.
Minimal residual disease in acute lymphoblastic leukemia.
Acute lymphoblastic leukemia: epidemiology.
Prognostic factors in adult acute lymphoblastic leukemia (ALL).
The generalized care of the patient with acute lymphoblastic leukemia.
Treatment of acute lymphoblastic leukemia in middle-age and older adults.
Pharmacology of acute lymphoblastic leukemia therapy.
Assessment of response to treatment.
T-cell acute lymphoblastic leukemia.
Burkitt lymphoma and leukemia.
Treatment of acute lymphoblastic leukemia in young adults.
Philadelphia chromosome positive acute lymphoblastic leukemia.
Molecular therapies.
Treatment of relapsed acute lymphoblastic leukemia.
Allogeneic stem cell transplantation for acute lymphoblastic leukemia in adults.
Hematopoietic stem cell transplantation in Philadelphia-positive acute lymphoblastic leukemia.
Special challenges: genetic polymorphisms and therapy.
Late consequences of therapy of acute lymphoblastic leukemia.
Immunotherapy for acute lymphoblastic leukemia.
Unique subtypes in acute lymphoblastic leukemia. The current explosion of new areas of controversy in the treatment of acute lymphocytic leukemia in adults and young adults makes this comprehensive book a much needed reference for hematologists and oncologists. This book assembles leading authorities from around the globe to cover the full spectrum of ALL subtypes and their treatments. Specific topics of discussion include indications for allogeneic bone marrow transplant in first complete remission, the role of minimal residual disease in making treatment decisions, the treatment of young adults, and the treatment of Philadelphia chromosome.